AbbVie’s $820M Trade Volume Ranks 107th as tLNP Acquisition Targets Autoimmune Breakthrough

On August 19, 2025, AbbVie (ABBV) saw a 0.18% decline in its stock price, with a trading volume of $0.82 billion, down 34.86% from the previous day, ranking 107th in market activity. The company finalized its acquisition of Capstan Therapeutics, integrating a Phase 1 clinical asset, CPTX2309, and a proprietary lipid nanoparticle (tLNP) platform. CPTX2309 targets B cell-mediated autoimmune diseases by generating in vivo CAR-T cells, aiming for durable remission without lymphodepleting chemotherapy. AbbVie highlighted the tLNP technology’s potential to advance cell programming and immune system reset strategies.

The acquisition aligns with AbbVie’s focus on immunology and oncology, expanding its pipeline with therapies designed to address unmet medical needs. Jonathon Sedgwick, senior vice president of discovery research, emphasized the strategic value of Capstan’s team and platform in accelerating innovation. The transaction underscores AbbVie’s commitment to in vivo therapies, which could differentiate its offerings in competitive therapeutic areas.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 1.98%, with a total return of 7.61% over 365 days. The strategy's Sharpe ratio was 0.94, indicating good risk-adjusted returns. However, the maximum drawdown of -29.16% highlights its vulnerability during market downturns.